Serum adipocytokine levels in patients with colorectal cancer

Abstract

Objectives: Adipose tissue, besides its main function as an energy storage depot, is currently considered an en­docrine organ that secretes several self-produced cytok­ines. Leptin and resistin play an important role in energy homeostasis, glucose, lipid metabolism and regulation of body weight. The aim of the current study was to deter­mine the concentration of leptin and resistin in pre-opera­tional and post-operational periods of patients diagnosed as colorectal cancer. Materials and methods: The body mass index (BMI) and values of leptin and resistin in blood at diagnosis were measured in 12 colorectal cancer patients in pre- and post-operational periods and in 12 age- and sex-matched controls. Serum leptin and resistin concentrations were measured by ELISA method. Results: Decreased leptin (1.95±0.62 ng/ml) and resis­tin (4.32±1.83 ng/ml) levels were found in pre-operational group compared with the control group (leptin: 6.12±0.82 ng/ml; resistin: 10.75±1.46 ng/ml) (p

Keywords

• Colorectal neoplasm, leptin, resistin serum

Kolerektal kanserli hastalarda serum adipositokin düzeyleri

Abstract

Amaç: Yağ dokusu, bir enerji deposu olan ana işlevinin yanında, bazı sitokinler salgılayarak bir endokrin organ olarak kabul edilir. Leptin ve rezistin, enerji homeostazi­sinde, glikoz, lipid metabolizmasında ve vücut ağırlığının düzenlenmesinde önemli bir rol oynamaktadır. Bu çalış­manın amacı, kolorektal kanserli hastalarda operasyon öncesi ve operasyon sonrası dönemlerde leptin ve rezis­tin konsantrasyonlarının belirlenmesidir. Gereç ve yöntem: Toplam 12 kolorektal kanserli hastada ameliyet öncesi ve sonrası dönemde ve yaş ve cinsiyet uyumlu 12 kişiden oluşan kontrol grubunda vücut kitle in­deksi (VKİ) ve kan örneklerinde leptin ve rezistin düzeyleri ölçüldü. Serum leptin ve rezistin konsantrasyonları ELISA ile yöntemi ile ölçüldü. Bulgular: Operasyon öncesi grup (leptin: 1.95±0.62 ng/ml; resistin 4.32±1.83 ng/ml) kontrol grubuna (leptin: 6.12±0.82 ng/ml; resistin: 10.75±1.46 ng/ml) göre karşı­laştırıldığında leptin ve rezistin düzeylerinde azalma göz­lemlendi (sırasıyla, p

Keywords

• Kolorektal kanser, leptin, rezistin, se­rum

References

1. Caan BJ, Coates AO, Slattery ML, Potter JD, Qusenberr CP, Edwards SM. Body size and the risk of colon cancer in large case-control study. Int J Obes 1998;22:178-84.
2. Housa D, Housava J, Vernerova Z, Haluzik M. Adipocytok- ines and cancer. Physiol Res 2006;55:233-44.
3. Wolf I, Sadetzki S, Kanety H, et al. Adiponectin, ghrelin and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006;106:966-73.
4. Baratta M. Leptin from a signal of adiposity to a hormone mediator in peripheral tissues. Med Sci Monit 2002;8:282– 92.
5. Friedman JM, Halaas J. Leptin and the regulation of body weight in mammals. Nature 1998;22:763–70.
6. Ukkola O. Resistin a mediator of obesity associated insu- lin resistance or an innocent bystander. Eur J Endocrinol 2002;147:571–4.
7. Kumor A, Daniel P, Pietruczuk M, Małecka PE. Serum lep- tin, adiponectin, and resistin concentration in colorectal ad- enoma and carcinoma (CC) patients. Int J Colorectal Dis 2009;24:275–81.
8. Arpaci F, Yılmaz MI, Ozet A, ve ark. Low serum leptin level in colon cancer patients without significant weight loss. Tu- mori 2002;88:147-9.

9. Simone ND, Nicuolo FD, Sanguinetti M, et al. Resistin regulates human choriocarcinoma cell invasive behavior and endothelial cell angiogenic processes. J Endocrinol 2006;189:691-9.
10. Karapanagiotou EM, Tsochatzis EA, Dilana KD, Tourkan- tonis I, Gratsias I, Syrigos KN. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer 2008;61:391-7.
11. Meier U, Gressner AM. Endocrine regulation of energy me- tabolism: review of pathobiochemical and clinical chemi- cal aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004;50:1511—25.
12. Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines as new promising markers of colorectal tumors: adiponec- tin for colorectal adenoma, and resistin and visfatin for col- orectal cancer. Cancer Sci 2010;101:1286-91.
13. Bolukbas F, Kilic H, Bolukbas C, ve ark. Serum leptin con- centration and advanced gastrointestinal cancers: a case controlled study. BMC Cancer 2004;4:29-33.
14. Simons JP, Schols AM, Campfirld L.A et al. Plasma con- centration of total leptin and human lung-cancer-associated cachexia. Clin Sci (Lond) 1997;93:273–7.
15. Wallace AM, Sattar N, McMillan DC. Effect of weight loss and the inflammatory response on leptin concentra- tion in gastrointestinal cancer patients. Clin Cancer Res 1998;4:2977–9.
16. Hardwick JC, Van Der Brink GR, Offerhause GJ. Leptin is a growth factor for colonic epithelial cells. Gastroenterology 2001;121:79–90.
17. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2005;207:12–22.
18. Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as bio- markers of gastric cancer. J Gastroenterol 2009;44:685–90.
19. Dalamaga M, Karmaniolas K, Nikolaidou A, et al. Adiponec- tin and resistin are associated with risk for myelodysplas- tic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. Eur J Cancer 2008;44:1744–53.
20. Dalamaga M, Karmaniolas K, Panagiotou A, et al. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case control study. Canc Causes Contr 2009;20:193-9.
21. Silswal N, Singh A.K, Aruna B, et al. Human resistin stimu- lates the pro-inflammatory cytokines TNF alpha and IL-12 in macrophages by NFkappaB dependent pathway. Bio- chem Biophys Res Commun 2005;334:1092–101.